CytomX Therapeutics Inc

Most Recent

  • uploads///Amgen collaborations
    Company & Industry Overviews

    A Look into Amgen’s Collaborations in 2H17

    Products under the Kirin–Amgen joint venture include Epogen, Neulasta, Aranesp, Nplate, and Neupogen.

    By Daniel Collins
  • uploads///Analysts Rating
    Company & Industry Overviews

    Analysts’ Recommendations for Amgen in October 2017

    Of the 24 analysts tracking Amgen (AMGN) in October 2017, ~42% of the analysts recommended a “buy” rating, and the rest suggested a ”hold.” On October 5, Amgen had a consensus 12-month target price of ~$189.35.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.